Seek Returns

ICLR vs. TEVA: ICON vs. Teva Pharmaceutical Stock Comparison

How do ICON (ICLR) and Teva Pharmaceutical (TEVA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

ICON (ICLR) and Teva Pharmaceutical (TEVA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ICLR is classified in Life Sciences Tools & Services while TEVA is classified in Pharmaceuticals.

ICON (ICLR) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for ICON (ICLR) and Teva Pharmaceutical (TEVA)
Profile ItemICLRTEVA
NameICON plcTeva Pharmaceutical Industries Ltd. ADR
Country/RegionIrelandIsrael
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesPharmaceuticals
GICS Sub-IndustryLife Sciences Tools & ServicesPharmaceuticals
Market Capitalization15.34 billion USD49.72 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateMay 15, 1998February 16, 1982
Security TypeCommon StockADR

Price Performance

Cumulative Growth

ICLR
TEVA
GSPC
Loading price history…
ICON (ICLR) vs. Teva Pharmaceutical (TEVA), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for ICON (ICLR) and Teva Pharmaceutical (TEVA). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for ICON (ICLR) and Teva Pharmaceutical (TEVA). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for ICON (ICLR) and Teva Pharmaceutical (TEVA)
MetricICLRTEVA
Total Return (1Y)30.55%79.58%
Total Return (3Y, Annualized)-6.05%69.94%
Total Return (5Y, Annualized)-5.40%35.86%

Risk Profile

Drawdown History

ICLR
TEVA
GSPC
Loading price history…
ICON (ICLR) vs. Teva Pharmaceutical (TEVA), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for ICON (ICLR) and Teva Pharmaceutical (TEVA). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for ICON (ICLR) and Teva Pharmaceutical (TEVA)
MetricICLRTEVA
Volatility (1Y, Annualized)68.62%33.95%
Beta (5Y)1.170.96
Max Drawdown (5Y)-76.87%-43.70%
Avg. Volume (3M)943.50K5.91M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ICLR and TEVA are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for ICON (ICLR) and Teva Pharmaceutical (TEVA)
MetricICLRTEVA
Sharpe Ratio (1Y)0.382.22
Sortino Ratio (1Y)0.523.94

Profitability

ROE (TTM)

Teva Pharmaceutical (TEVA) at 6.65% sits in the top ROE quartile, while ICON (ICLR) at 4.70% is closer to the peer norm — stronger capital efficiency for TEVA.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70%

Max
109.18%
Q3
6.23%
ICLR
4.70%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.65%

Max
109.18%
TEVA
6.65%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
ICON (ICLR) vs. Teva Pharmaceutical (TEVA): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

ICON (ICLR) at 5.26% retains a top-quartile share of revenue as profit, ahead of Teva Pharmaceutical (TEVA) at 2.94%, which keeps about the industry-typical share.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.26%

Max
18.05%
ICLR
5.26%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.94%

Max
18.05%
Q3
4.78%
TEVA
2.94%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
ICON (ICLR) vs. Teva Pharmaceutical (TEVA): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Teva Pharmaceutical (TEVA) at 27.40% operates in the top operating margin quartile, ahead of ICON (ICLR) at 10.73%, which runs around its industry’s norm.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.73%

Max
83.12%
Q3
14.77%
ICLR
10.73%
Median
0.00%
Q1
-78.82%
Min
-207.40%

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.40%

Max
83.12%
TEVA
27.40%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
ICON (ICLR) vs. Teva Pharmaceutical (TEVA): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for ICON (ICLR) and Teva Pharmaceutical (TEVA)
MetricICLRTEVA
ROE (TTM)4.70%6.65%
ROA (TTM)0.85%5.35%
Net Margin (TTM)5.26%2.94%
Operating Margin (TTM)10.73%27.40%
Gross Margin (TTM)23.44%53.51%

Growth

Revenue Growth

Both ICON (ICLR) at 0.76% and Teva Pharmaceutical (TEVA) at 4.31% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
ICON (ICLR) vs. Teva Pharmaceutical (TEVA): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: ICON (ICLR) reports EPS growth of -71.56%, ranked against its industry; Teva Pharmaceutical (TEVA) has no EPS growth figure this period.

Loading chart…
ICON (ICLR) vs. Teva Pharmaceutical (TEVA): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for ICON (ICLR) and Teva Pharmaceutical (TEVA)
MetricICLRTEVA
Revenue Growth (YoY)0.76%4.31%
Revenue Growth (3Y CAGR)2.15%4.96%
EPS Growth (YoY)-71.56%--
EPS Growth (3Y CAGR)-23.82%--

Financial Strength

Current Ratio (MRQ)

Both ICON (ICLR) at 1.32 and Teva Pharmaceutical (TEVA) at 0.95 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.32

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ICLR
1.32
Min
0.10

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.95

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
TEVA
0.95
Min
0.10
Loading chart…
ICON (ICLR) vs. Teva Pharmaceutical (TEVA): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

ICON (ICLR) at 0.38 is near its industry mid-range for debt-to-equity ratio, while Teva Pharmaceutical (TEVA) at 2.13 sits above its benchmark range, pointing to a heavier debt load relative to equity.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max
1.42
Q3
0.65
ICLR
0.38
Median
0.15
Q1
0.02
Min
0.00

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.13

TEVA
2.13
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
ICON (ICLR) vs. Teva Pharmaceutical (TEVA): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for ICON (ICLR) and Teva Pharmaceutical (TEVA)
MetricICLRTEVA
Current Ratio (MRQ)1.320.95
Debt / Equity (MRQ)0.382.13
Net Debt / EBITDA5.552.93

Dividends

Dividend Yield (TTM)

Neither ICON (ICLR) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ICLR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

TEVA
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
ICON (ICLR) vs. Teva Pharmaceutical (TEVA): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither ICON (ICLR) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ICLR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

TEVA
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
ICON (ICLR) vs. Teva Pharmaceutical (TEVA): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for ICON (ICLR) and Teva Pharmaceutical (TEVA)
MetricICLRTEVA
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Both look expensive on trailing earnings: ICON (ICLR) at 81.90 sits in the richer P/E ratio quartile, and Teva Pharmaceutical (TEVA) at 99.09 is richer still, above its industry range.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

81.90

Max
85.34
ICLR
81.90
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

99.09

TEVA
99.09
Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
ICON (ICLR) vs. Teva Pharmaceutical (TEVA): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Both ICON (ICLR) at 1.86 and Teva Pharmaceutical (TEVA) at 2.89 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.86

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
ICLR
1.86
Min
0.01

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.89

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
TEVA
2.89
Min
0.01
Loading chart…
ICON (ICLR) vs. Teva Pharmaceutical (TEVA): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

ICON (ICLR) at 1.68 sits in the lower P/B ratio quartile against book while Teva Pharmaceutical (TEVA) at 6.23 is valued near its industry’s middle — ICLR is cheaper on assets, though weigh it against ROE and asset quality.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.68

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
ICLR
1.68
Min
-5.59

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.23

Max
13.53
Q3
6.54
TEVA
6.23
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
ICON (ICLR) vs. Teva Pharmaceutical (TEVA): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for ICON (ICLR) and Teva Pharmaceutical (TEVA)
MetricICLRTEVA
P/E Ratio (TTM)81.9099.09
P/S Ratio (TTM)1.862.89
P/B Ratio (MRQ)1.686.23
Free Cash Flow Yield (TTM)3.51%3.00%